Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • Cantor Fitzgerald reiterates neutral rating with USD 210.00 price target.
  • Molina Healthcare carries consensus “Hold” rating from MarketBeat analysts.
  • Analysts cite revised valuations after sector-wide healthcare coverage adjustments.

Cantor Fitzgerald reaffirmed its “neutral” rating on shares of Molina Healthcare (NYSE: MOH - Get Free Report) in a research note issued Tuesday, according to Benzinga. The firm set a target price of USD 210.00, suggesting potential upside of just over 20% from the company’s most recent closing price.

The reaffirmation follows a series of rating and target price revisions from other research firms during July. Morgan Stanley lowered its stance on Molina Healthcare from “overweight” to “equal weight,” cutting its target from USD 364.00 to USD 266.00. Barclays also revised its target downward, from USD 270.00 to USD 186.00, assigning an “equal weight” rating. Truist Financial maintained a “hold” rating but reduced its target price from USD 335.00 to USD 180.00. Similarly, Mizuho shifted its target from USD 400.00 to USD 330.00 while retaining an “outperform” rating. Robert W. Baird made one of the steepest revisions, lowering its target from USD 373.00 to USD 179.00 while assigning a “neutral” rating.

According to MarketBeat data, Molina Healthcare currently holds a consensus rating of “Hold” from analysts, with an average target price of USD 242.91. Out of the firms covering the stock, three have issued a “Buy” rating, while ten have opted for “Hold.”

Molina Healthcare operates as a managed healthcare provider, primarily serving low-income individuals and families through Medicaid, Medicare, and state insurance marketplace programs. The company reports across four segments—Medicaid, Medicare, Marketplace, and Other—and has a service footprint across 19 states in the U.S. Founded in 1980, Molina is headquartered in Long Beach, California.